Education, Science, Technology, Innovation and Life
Open Access
Sign In
  1. Home
  2. Journals
  3. MEDS Public Health and Preventive Medicine
  4. Vol 3, Issue 6, 2023

The role of polyunsaturated fatty acids: The possibility of diet intervention in Parkinson's disease

Download as PDF

DOI: 10.23977/phpm.2023.030606 | Downloads: 12 | Views: 375

Author(s)

Haoan Tang 1, Shaojia Chen 1, Hongjun Liu 1, Xu Chen 1

Affiliation(s)

1 Wuxi Medical School, Jiangnan University, Wuxi, Jiangsu, 214122, China

Corresponding Author

Haoan Tang

ABSTRACT

Parkinson's disease (PD) is a prevalent neurodegenerative illness that causes a gradual loss of dopaminergic (DA) neurons in the substantia nigra (SN). The pathophysiology of PD is still unknown, but unusual lipid metabolism has just been discovered as one of the major variables linked with the disease. foundation and practical guidelines for the prevention and treatment of PD. This article discussed the role of polyunsaturated fatty acids (PUFAs) in the pathogenesis of PD, compared the effects of omega-3 (ω-3) and omega-6 (ω-6) in PD, analyzed the treatment mechanism and methods of ω-3 PUFAs in PD, and proposed new ideas for early intervention of PD. This paper first introduced the classification and source of lipid acids, then analyzed the regulatory role of PUFAs in the pathological process of PD, and then elaborated the neuroprotective effects of ω-3 PUFAs on PD, including anti-inflammation, anti-apoptosis, anti-oxidation, promoting neuron growth and differentiation, improving neurotransmitter balance. Finally, this paper proposes some dietary intervention suggestions, such as increasing the intake of ω-3 and reducing the intake of ω-6, in order to maintain the balance of lipid metabolism and delay the progression of PD. This paper aims to provide a new theoretical basis and practical guidance for the prevention and treatment of PD.

KEYWORDS

Parkinson's disease, polyunsaturated fatty acids, omega-3, omega-6, diet intervention

CITE THIS PAPER

Haoan Tang, Shaojia Chen, Hongjun Liu, Xu Chen, The role of polyunsaturated fatty acids: The possibility of diet intervention in Parkinson's disease. MEDS Public Health and Preventive Medicine (2023) Vol. 3: 36-45. DOI: http://dx.doi.org/10.23977/phpm.2023.030606.

REFERENCES

[1] Kalia, L.V. and A.E. Lang, Parkinson's disease. Lancet, 2015. 386(9996): p. 896-912.
[2] Alarcon-Gil, J., et al., Neuroprotective and Anti-Inflammatory Effects of Linoleic Acid in Models of Parkinson's Disease: The Implication of Lipid Droplets and Lipophagy. Cells, 2022. 11(15).
[3] Fanning, S., et al., Lipidomic Analysis of α-Synuclein Neurotoxicity Identifies Stearoyl CoA Desaturase as a Target for Parkinson Treatment. Mol Cell, 2019. 73(5): p. 1001-1014.e8.
[4] Beal, M.F., et al., Isotope-reinforced polyunsaturated fatty acids improve Parkinson's disease-like phenotype in rats overexpressing α-synuclein. Acta Neuropathol Commun, 2020. 8(1): p. 220.
[5] de Lau, L.M., et al., Dietary fatty acids and the risk of Parkinson disease: the Rotterdam study. Neurology, 2005. 64(12): p. 2040-2045.
[6] Liu, X., et al., Formation of dopamine adducts derived from brain polyunsaturated fatty acids: mechanism for Parkinson disease. J Biol Chem, 2008. 283(50): p. 34887-34895.
[7] Hernando, S., et al., Beneficial effects of n-3 polyunsaturated fatty acids administration in a partial lesion model of Parkinson's disease: The role of glia and NRf2 regulation. Neurobiol Dis, 2019. 121: p. 252-262.
[8] Barros, A.S., et al., Impact of the Chronic Omega-3 Fatty Acids Supplementation in Hemiparkinsonism Model Induced by 6-Hydroxydopamine in Rats. Basic Clin Pharmacol Toxicol, 2017. 120(6): p. 523-531.
[9] Schönfeld, P. and L. Wojtczak, Short- and medium-chain fatty acids in energy metabolism: the cellular perspective. J Lipid Res, 2016. 57(6): p. 943-954.
[10] Canbay, A., L. Bechmann, and G. Gerken, Lipid metabolism in the liver. Z Gastroenterol, 2007. 45(1): p. 35-41.
[11] Kapoor, B., et al., Dietary Polyunsaturated Fatty Acids (PUFAs): Uses and Potential Health Benefits. Curr Nutr Rep, 2021. 10(3): p. 232-242.
[12] McCowen, K.C. and B.R. Bistrian, Essential fatty acids and their derivatives. Curr Opin Gastroenterol, 2005. 21(2): p. 207-215.
[13] Das, U.N., Essential Fatty acids - a review. Curr Pharm Biotechnol, 2006. 7(6): p. 467-482.
[14] Betsholtz, C., Lipid transport and human brain development. Nat Genet, 2015. 47(7): p. 699-701.
[15] Youdim, K.A., A. Martin, and J.A. Joseph, Essential fatty acids and the brain: possible health implications. Int J Dev Neurosci, 2000. 18(4-5): p. 383-399.
[16] Bianchi, V.E., P.F. Herrera, and R. Laura, Effect of nutrition on neurodegenerative diseases. A systematic review. Nutr Neurosci, 2021. 24(10): p. 810-834.
[17] Kumar, A., et al., Exploring the molecular approach of COX and LOX in Alzheimer's and Parkinson's disorder. Mol Biol Rep, 2020. 47(12): p. 9895-9912.
[18] Li, P. and C. Song, Potential treatment of Parkinson's disease with omega-3 polyunsaturated fatty acids. Nutr Neurosci, 2022. 25(1): p. 180-191.
[19] Manes, M., et al., Long-term efficacy of docosahexaenoic acid (DHA) for Spinocerebellar Ataxia 38 (SCA38) treatment: An open label extension study. Parkinsonism Relat Disord, 2019. 63: p. 191-194.
[20] Hachem, M. and H. Nacir, Emerging Role of Phospholipids and Lysophospholipids for Improving Brain Docosahexaenoic Acid as Potential Preventive and Therapeutic Strategies for Neurological Diseases. Int J Mol Sci, 2022. 23(7).
[21] Serhan, C.N., et al., Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their endogenous aspirin-triggered epimers. Lipids, 2004. 39(11): p. 1125-1132.
[22] Ajith, T.A., A Recent Update on the Effects of Omega-3 Fatty Acids in Alzheimer's Disease. Curr Clin Pharmacol, 2018. 13(4): p. 252-260.
[23] Alessandri, J.M., et al., Polyunsaturated fatty acids in the central nervous system: evolution of concepts and nutritional implications throughout life. Reprod Nutr Dev, 2004. 44(6): p. 509-518.
[24] Yu, J.Z., et al., N-3 polyunsaturated fatty acids promote astrocyte differentiation and neurotrophin production independent of cAMP in patient-derived neural stem cells. Mol Psychiatry, 2021. 26(9): p. 4605-4615.
[25] Su, K.P., et al., Omega-3 fatty acids in the prevention of interferon-alpha-induced depression: results from a randomized, controlled trial. Biol Psychiatry, 2014. 76(7): p. 559-566.
[26] Borsini, A., et al., Omega-3 polyunsaturated fatty acids protect against inflammation through production of LOX and CYP450 lipid mediators: relevance for major depression and for human hippocampal neurogenesis. Mol Psychiatry, 2021. 26(11): p. 6773-6788.
[27] Baker, E.J., et al., Metabolism and functional effects of plant-derived omega-3 fatty acids in humans. Prog Lipid Res, 2016. 64: p. 30-56.
[28] Piermartiri, T., et al., α-Linolenic Acid, A Nutraceutical with Pleiotropic Properties That Targets Endogenous Neuroprotective Pathways to Protect against Organophosphate Nerve Agent-Induced Neuropathology. Molecules, 2015. 20(11): p. 20355-20380.
[29] Cavina, M., et al., Supplementation with alpha-linolenic acid and inflammation: a feasibility trial. Int J Food Sci Nutr, 2021. 72(3): p. 386-390.
[30] Yuan, Q., et al., The review of alpha-linolenic acid: Sources, metabolism, and pharmacology. Phytother Res, 2022. 36(1): p. 164-188.
[31] Egert, S., et al., Effects of an energy-restricted diet rich in plant-derived α-linolenic acid on systemic inflammation and endothelial function in overweight-to-obese patients with metabolic syndrome traits. Br J Nutr, 2014. 112(8): p. 1315-1322.
[32] Litwiniuk, A., et al., The Effects of Alpha-Linolenic Acid on the Secretory Activity of Astrocytes and β Amyloid-Associated Neurodegeneration in Differentiated SH-SY5Y Cells: Alpha-Linolenic Acid Protects the SH-SY5Y cells against β Amyloid Toxicity. Oxid Med Cell Longev, 2020. 2020: p. 8908901.
[33] Qu, Y., et al., Relationship between high dietary fat intake and Parkinson's disease risk: a meta-analysis. Neural Regen Res, 2019. 14(12): p. 2156-2163.
[34] Kursun, O., et al., Arachidonic Acid Metabolites in Neurologic Disorders. CNS Neurol Disord Drug Targets, 2022. 21(2): p. 150-159.
[35] Wyss-Coray, T. and L. Mucke, Inflammation in neurodegenerative disease--a double-edged sword. Neuron, 2002. 35(3): p. 419-432.
[36] Wang, Q., Y. Liu, and J. Zhou, Neuroinflammation in Parkinson's disease and its potential as therapeutic target. Transl Neurodegener, 2015. 4: p. 19.
[37] Whelan, J. and K. Fritsche, Linoleic acid. Adv Nutr, 2013. 4(3): p. 311-322.
[38] Montine, K.S., et al., Isoprostanes and related products of lipid peroxidation in neurodegenerative diseases. Chem Phys Lipids, 2004. 128(1-2): p. 117-124.
[39] Fessel, J.P., et al., Isofurans, but not F2-isoprostanes, are increased in the substantia nigra of patients with Parkinson's disease and with dementia with Lewy body disease. J Neurochem, 2003. 85(3): p. 645-650.
[40] Sugiyama, A. and J. Sun, Immunochemical detection of lipid hydroperoxide- and aldehyde-modified proteins in diseases. Subcell Biochem, 2014. 77: p. 115-125.
[41] Di Domenico, F., A. Tramutola, and D.A. Butterfield, Role of 4-hydroxy-2-nonenal (HNE) in the pathogenesis of alzheimer disease and other selected age-related neurodegenerative disorders. Free Radic Biol Med, 2017. 111: p. 253-261.
[42] Dexter, D.T., et al., Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem, 1989. 52(2): p. 381-389.
[43] Dalfó, E., et al., Evidence of oxidative stress in the neocortex in incidental Lewy body disease. J Neuropathol Exp Neurol, 2005. 64(9): p. 816-830.
[44] Dexter, D., et al., Lipid peroxidation as cause of nigral cell death in Parkinson's disease. Lancet, 1986. 2(8507): p. 639-643.
[45] Siddique, Y.H., F. Naz, and S. Jyoti, Effect of capsaicin on the oxidative stress and dopamine content in the transgenic Drosophila model of Parkinson's disease. Acta Biol Hung, 2018. 69(2): p. 115-124.
[46] Gupta, S.P., et al., Does restraining nitric oxide biosynthesis rescue from toxins-induced parkinsonism and sporadic Parkinson's disease? Mol Neurobiol, 2014. 49(1): p. 262-275.
[47] Wang, T., et al., Hydroxysafflor Yellow A Attenuates Lipopolysaccharide-Induced Neurotoxicity and Neuroinflammation in Primary Mesencephalic Cultures. Molecules, 2018. 23(5).
[48] Huang, T.C., et al., Resveratrol protects rats from Aβ-induced neurotoxicity by the reduction of iNOS expression and lipid peroxidation. PLoS One, 2011. 6(12): p. e29102.
[49] Mori, M.A., et al., Neuroprotective effect of omega-3 polyunsaturated fatty acids in the 6-OHDA model of Parkinson's disease is mediated by a reduction of inducible nitric oxide synthase. Nutr Neurosci, 2018. 21(5): p. 341-351.
[50] Ilaghi, M., et al., The apelin/APJ signaling system and cytoprotection: Role of its cross-talk with kappa opioid receptor. Eur J Pharmacol, 2022. 936: p. 175353.
[51] Gao, Z., et al., Apelin‑13 alleviates diabetic nephropathy by enhancing nitric oxide production and suppressing kidney tissue fibrosis. Int J Mol Med, 2021. 48(3).
[52] Reaux, A., et al., Distribution of apelin-synthesizing neurons in the adult rat brain. Neuroscience, 2002. 113(3): p. 653-662.
[53] Acar, N., et al., The effect of docosahexaenoic acid on apelin distribution of nervous system in the experimental mouse model of Parkinson's disease. Tissue Cell, 2019. 56: p. 41-51.
[54] Akbar, M. and H.Y. Kim, Protective effects of docosahexaenoic acid in staurosporine-induced apoptosis: involvement of phosphatidylinositol-3 kinase pathway. J Neurochem, 2002. 82(3): p. 655-665.
[55] Heuer, A., et al., Unilateral nigrostriatal 6-hydroxydopamine lesions in mice I: motor impairments identify extent of dopamine depletion at three different lesion sites. Behav Brain Res, 2012. 228(1): p. 30-43.
[56] Gash, D.M., Z. Zhang, and G. Gerhardt, Neuroprotective and neurorestorative properties of GDNF. Ann Neurol, 1998. 44(3 Suppl 1): p. S121-125.
[57] Horger, B.A., et al., Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons. J Neurosci, 1998. 18(13): p. 4929-4937.
[58] Koeberle, P.D. and M. Bähr, The upregulation of GLAST-1 is an indirect antiapoptotic mechanism of GDNF and neurturin in the adult CNS. Cell Death Differ, 2008. 15(3): p. 471-483.
[59] Lin, L.F., et al., GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science, 1993. 260(5111): p. 1130-1136.
[60] Hyman, C., et al., BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature, 1991. 350(6315): p. 230-239.
[61] Siegel, G.J. and N.B. Chauhan, Neurotrophic factors in Alzheimer's and Parkinson's disease brain. Brain Res Brain Res Rev, 2000. 33(2-3): p. 199-227.
[62] Ceccarini, M.R., et al., The Polyunsaturated Fatty Acid EPA, but Not DHA, Enhances Neurotrophic Factor Expression through Epigenetic Mechanisms and Protects against Parkinsonian Neuronal Cell Death. Int J Mol Sci, 2022. 23(24).
[63] Shashikumar, S., et al., Alpha-linolenic acid suppresses dopaminergic neurodegeneration induced by 6-OHDA in C. elegans. Physiol Behav, 2015. 151: p. 563-569.
[64] Mazza, M., et al., Omega-3 fatty acids and antioxidants in neurological and psychiatric diseases: an overview. Prog Neuropsychopharmacol Biol Psychiatry, 2007. 31(1): p. 12-26.
[65] Kamel, F., et al., Dietary fat intake, pesticide use, and Parkinson's disease. Parkinsonism Relat Disord, 2014. 20(1): p. 82-87.
[66] Mischley, L.K., R.C. Lau, and R.D. Bennett, Role of Diet and Nutritional Supplements in Parkinson's Disease Progression. Oxid Med Cell Longev, 2017. 2017: p. 6405278.
[67] Shamoto-Nagai, M., et al., In parkinsonian substantia nigra, alpha-synuclein is modified by acrolein, a lipid-peroxidation product, and accumulates in the dopamine neurons with inhibition of proteasome activity. J Neural Transm (Vienna), 2007. 114(12): p. 1559-1567.
[68] Yoo, D., et al., Dietary intake and plasma levels of polyunsaturated fatty acids in early-stage Parkinson's disease. Sci Rep, 2021. 11(1): p. 12489.
[69] Beitz, J.M., Parkinson's disease: a review. Front Biosci (Schol Ed), 2014. 6(1): p. 65-74.
[70] da Silva, T.M., et al., Depression in Parkinson's disease: a double-blind, randomized, placebo-controlled pilot study of omega-3 fatty-acid supplementation. J Affect Disord, 2008. 111(2-3): p. 351-359.
[71] Liddelow, S.A., et al., Neurotoxic reactive astrocytes are induced by activated microglia. Nature, 2017. 541(7638): p. 481-487.
[72] Chen, R., X. Gu, and X. Wang, α-Synuclein in Parkinson's disease and advances in detection. Clin Chim Acta, 2022. 529: p. 76-86.
[73] Cheng, A., et al., Development of FABP3 ligands that inhibit arachidonic acid-induced α-synuclein oligomerization. Brain Res, 2019. 1707: p. 190-197.
[74] Sharon, R., et al., The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson's disease. Neuron, 2003. 37(4): p. 583-595.
[75] Shioda, N., et al., FABP3 protein promotes α-synuclein oligomerization associated with 1-methyl-1,2,3,6-tetrahydropiridine-induced neurotoxicity. J Biol Chem, 2014. 289(27): p. 18957-18965.
[76] Haga, H., et al., Novel fatty acid-binding protein 3 ligand inhibits dopaminergic neuronal death and improves motor and cognitive impairments in Parkinson's disease model mice. Pharmacol Biochem Behav, 2020. 191: p. 172891.
[77] Broersen, K., V. Ruiperez, and B. Davletov, Structural and Aggregation Properties of Alpha-Synuclein Linked to Phospholipase A2 Action. Protein Pept Lett, 2018. 25(4): p. 368-378.
[78] Matveyenka, M., K. Zhaliazka, and D. Kurouski, Unsaturated fatty acids uniquely alter aggregation rate of α-synuclein and insulin and change the secondary structure and toxicity of amyloid aggregates formed in their presence. Faseb j, 2023. 37(7): p. e22972.
[79] Zhang, J., et al., Targeted fatty acid metabolomics to discover Parkinson's disease associated metabolic alteration. J Mass Spectrom, 2021. 56(10): p. e4781.
[80] Xicoy, H., et al., Shared genetic etiology between Parkinson's disease and blood levels of specific lipids. NPJ Parkinsons Dis, 2021. 7(1): p. 23.
[81] Miyake, Y., et al., Dietary fat intake and risk of Parkinson's disease: a case-control study in Japan. J Neurol Sci, 2010. 288(1-2): p. 117-122.
[82] Veenvliet, J.V. and M.P. Smidt, Molecular mechanisms of dopaminergic subset specification: fundamental aspects and clinical perspectives. Cell Mol Life Sci, 2014. 71(24): p. 4703-4707.

Subscription
E-Mail Alert
Most popular papers
Call for Special Issue
Publication Ethics & OA Statement
Plagiarism Policy
Contact Us
Downloads: 1928
Visits: 86969

Sponsors, Associates, and Links

All published work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2016 - 2031 Clausius Scientific Press Inc. All Rights Reserved.